Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more
Hello and welcome back to the new Endpoints Weekly. It was another busy week in the biopharma world and we’ve got all of the headlines for you below. We also had an
Hello and welcome back to the new Endpoints Weekly. It was another busy week in the biopharma world and we’ve got all of the headlines for you below.
We also had an
